flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 FLOW: outcome results for GLP-1RA Semaglutide in Patients with Heart

Description

They help manage mealtime surges in blood sugar, and then help manage blood sugar between meals or at night

This increases: hepatic fat oxidation energy expenditure triglyceride mobilization References: Habegger KM et al., Nature Medicine , 2010 Kim T et al., Cell Metabolism , 2018 Clinical Trial Evidence Obesity (Phase 2) Key outcomes: up to 24% body weight reduction majority of weight loss from fat mass Reference: Type 2 Diabetes Observed effects: HbA1c reduction improved glycemic control reduced insulin resistance Reference: Body Composition Effects Retatrutide appears to: reduce visceral adipose tissue reduce hepatic steatosis preserve lean mass when combined with resistance training Reference: Gastaldelli A et al., Diabetes , 2020 Neurological Research Context GLP-1 receptors are expressed in multiple brain regions including: hippocampus hypothalamus cortex These pathways may influence: neuroinflammation neuronal energy metabolism cognitive signaling Reference: Hlscher C, Nature Reviews Neuroscience , 2014 Cardiovascular and Renal Effects Incretin therapies have demonstrated: improved endothelial function reduced systemic inflammation lower cardiovascular risk markers Reference: Marso SP et al., NEJM , 2016 Safety and Tolerability Common adverse events in trials include: nausea vomiting diarrhea constipation These are generally dose-dependent and improve with titration

The authors concluded, "Treatment with GLP-1 receptor agonists was associated with lower all-cause mortality among patients with type 2 diabetes, advanced-stage CKD, and ESKD than was treatment with DPP-4 inhibitors

The most commonly reported issues include nausea (especially during dose increases), gastrointestinal disturbances , reduced sleep quality, elevated resting heart rate (one user noted a 10 bpm increase by week 4), and acid reflux when eating late in the day